Medicine and Dentistry
Radiation Therapy
100%
Diseases
60%
Overall Survival
47%
Uterine Cancer
31%
Hazard Ratio
30%
Brachytherapy
26%
Malignant Neoplasm
21%
Diffuse Large B-Cell Lymphoma
20%
Breast Cancer
19%
Connective Tissue Cancer
19%
Intensity Modulated Radiation Therapy
19%
Multiple Myeloma
19%
Chimeric Antigen Receptor T-Cell Immunotherapy
19%
External Beam Radiotherapy
19%
Lymphocytopenia
17%
Cancer Therapy
17%
Progression Free Survival
16%
Recurrent Disease
16%
Neoplasm
15%
Proportional Hazards Model
14%
Cancer
13%
Cancer Radiotherapy
13%
Quality of Life
12%
Cervical Cancer
12%
Chemoradiotherapy
12%
Neck
11%
Prostate Cancer
11%
B-Cell Lymphoma
11%
Proton Therapy
11%
Magnetic Resonance Imaging
11%
Disease Specific Survival
10%
Long Term Survival
10%
Hysterectomy
10%
Local Therapy
10%
Large-Cell Lymphoma
10%
Head and Neck Cancer
9%
Pelvic Floor Dysfunction
9%
Adaptive Radiotherapy
9%
Lymphatic Disease
9%
Lung Metastasis
9%
Radiation Biology
9%
Interstitial Brachytherapy
9%
Angiosarcoma
9%
Lymphedema
9%
Patient Selection
9%
Mesentery
9%
Non Small Cell Lung Cancer
9%
Soft Tissue Sarcoma
9%
Scalp
9%
Gastrointestinal Tract
9%
Keyphrases
Radiation Therapy
65%
Hazard Ratio
32%
Overall Survival
31%
Local Control
30%
Brachytherapy
23%
Multivariable
22%
Diffuse Large B-cell Lymphoma (DLBCL)
21%
Treatment Modalities
19%
Sarcoma
19%
Intensity-modulated Radiation Therapy
19%
Chimeric Antigen Receptor T-cell Therapy
19%
Combined Modality Therapy
18%
Progression-free Survival
18%
Lymphopenia
17%
Radiotherapy
16%
Uterine Cancer
14%
Aggressive B-cell Lymphoma
14%
Disease-specific Survival
13%
Hematotoxicity
13%
Cervical Cancer
13%
Gynecologic Malignancies
13%
Cancer Treatment
12%
Soft Tissue Sarcoma
12%
External Beam Radiotherapy
12%
Lymphoma Patients
12%
Head-and-neck
11%
Definitive Chemoradiation
11%
Prostate Cancer
11%
Surgery Therapy
11%
Bulky Disease
10%
Definitive Treatment
10%
Clinical Outcomes
10%
Local Therapy
10%
Long-term Survival
10%
Large B-cell Lymphoma
10%
Single Implant
9%
Lung Metastasis
9%
Non-small Cell Lung Cancer (NSCLC)
9%
Definitive Radiotherapy
9%
Patient Selection
9%
Oligometastases
9%
Protease Inhibitors
9%
Image-guided
9%
Intensity-modulated Proton Therapy
9%
HDR Brachytherapy
9%
Anal Cancer
9%
Lymphatic Abnormalities
9%
Cancer-related
9%
Scalp
9%
Progress Management
9%
Pharmacology, Toxicology and Pharmaceutical Science
Diseases
63%
Overall Survival
49%
Chemoradiation Therapy
31%
Chemotherapy
24%
Malignant Neoplasm
22%
Lymphocytopenia
19%
Chimeric Antigen Receptor
19%
Uterine Cervix Cancer
19%
Progression Free Survival
17%
Retrospective Study
11%
B Cell Lymphoma
11%
Large Cell Lymphoma
11%
Diffuse Large B Cell Lymphoma
10%
Recurrent Disease
9%
Connective Tissue Cancer
9%
Lung Metastasis
9%
Cytopenia
9%
Esophagus Cancer
9%
Multiple Myeloma
9%
HIV
9%
Anus Cancer
9%
Proteinase Inhibitor
9%
Breast Cancer
9%
Non Small Cell Lung Cancer
9%
Prostate Cancer
9%
Metastasis
7%
Disease Specific Survival
6%